加勒比地区开角型青光眼选择性激光小梁成形术的长期结局
该研究是对西印度群岛青光眼激光研究及其预试验近8年汇总数据的回顾分析,纳入133名非裔加勒比开角型青光眼成人共265眼,评估单药选择性激光小梁成形术(SLT)的长期疗效。结果显示,8年间平均眼压持续显著低于基线,初次SLT无药物生存期中位数为85.4个月,按需重复SLT的94个月无药物生存率约71%。
要点
- 单药SLT可使非裔加勒比开角型青光眼患者眼压显著下降并维持近8年。
- 初次SLT无药物生存期中位数为85.4个月。
- 按需重复SLT的94个月无药物生存率约为71%。
核心结论
- 单药SLT按需重复可为大多数非裔加勒比原发性开角型青光眼成人安全地显著降低眼压并维持近8年。
研究设计与样本
- 研究为西印度群岛青光眼激光研究及其预试验汇总数据的回顾分析,随访近8年(中位数3.2年,四分位距2.1-7.1年)。
- 研究设置于圣卢西亚和多米尼克的三家眼科诊所,纳入接受≤2种药物治疗的轻中度开角型青光眼非裔加勒比成人(预试验61例,主研究72例)。
- 干预包括药物洗脱、基线眼压测定和双侧360度SLT,随访至94个月,按预设标准重复SLT。
主要发现
- 汇总数据集包括133名非裔加勒比参与者的265眼。
- 右眼和左眼平均基线眼压分别为21.2(3.4)mmHg和21.2(3.9)mmHg。
- 8年间右眼平均眼压范围为12.8至15.7 mmHg,左眼为13.1至15.8 mmHg,与基线比较均P < .0001。
- 初次SLT的无药物生存期中位数在双眼均为85.4个月。
- 按需重复SLT的94个月无药物生存率右眼为71.2%,左眼为71.7%。
关键数值与推荐
- 主要结局为平均眼压较基线的下降。
- 次要结局为按需重复SLT下的无药物生存。
- 重复SLT依据预设标准进行。
临床怎么用
- 对于非裔加勒比开角型青光眼成人,单药SLT可作为有效降低眼压并延迟或预防青光眼相关视野丧失的治疗选择。
- 在资源有限地区,按需重复SLT可能有助于长期控制眼压并减少药物依赖。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To characterize long-term clinical outcomes of monotherapy selective laser trabeculoplasty (SLT) in Afro-Caribbean patients with open-angle glaucoma (OAG). DESIGN: This was a post hoc analysis of nearly 8 years (median, 3.2; interquartile range, 2.1-7.1) of pooled data from the West Indies Glaucoma Laser Study and its preliminary study. METHODS: Setting: Three eye care practices in Saint Lucia and Dominica. PARTICIPANTS: Afro-Caribbean adults with mild-moderate OAG treated with ≤2 medications (61 in preliminary study, 72 in West Indies Glaucoma Laser Study). INTERVENTION: Participants underwent medication washout, baseline intraocular pressure (IOP) determination, and bilateral 360-degree SLT. Participants were followed for up to 94 months. Repeat SLT was performed according to prespecified criteria. MAIN OUTCOME MEASURES: The primary outcome was mean IOP reduction from baseline. The secondary outcome was medication-free survival with SLT repeated as needed. RESULTS: The pooled data set included 265 eyes of 133 Afro-Caribbean participants. The mean (standard deviation) baseline IOP was 21.2 (3.4) and 21.2 (3.9) mmHg in right and left eyes, respectively. Over 8 years, the mean IOP ranged from 12.8 to 15.7 mm Hg and from 13.1 to 15.8 mm Hg, respectively (P < .0001 for every comparison with baseline). The median medication-free survival time for initial SLT was 85.4 months in both eyes. The 94-month medication-free survival of SLT repeated as needed was 71.2% and 71.7%, respectively. CONCLUSIONS: Monotherapy SLT, repeated as needed, safely provides significant IOP reductions in most Afro-Caribbean adults with primary OAG through nearly 8 years of follow-up and has significant potential to delay or prevent glaucoma-related vision loss in black patients in low-resource regions.
引用
- Realini T, Shillingford-Ricketts H, Burt D, et al. Long-Term Outcomes of Selective Laser Trabeculoplasty for Open-Angle Glaucoma in the Caribbean. Am J Ophthalmol. 2021. PMID: 34153267. doi:10.1016/j.ajo.2021.06.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。